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Hexon proteinHuman adenovirus (HAdV) is a cause of signiﬁcant morbidity and mortality in immunocompromised
patients, especially after stem cell transplantation (SCT). Viral clearance has been attributed to CD4+ T-cell
responses against the Hexon-protein, but the frequency of speciﬁc THELPER cells is extremely low or not
detectable ex vivo and preference for different CD4+ T-cell epitopes is variable among individuals. We
therefore analyzed 44 healthy donors and 6 SCT-recipients for Hexon-speciﬁc CD4+-responses ex vivo, to
identify epitopes which would be broadly applicable. We selected 19 candidate epitopes with predicted
restriction to HLA-DR1/DR3/DR4/DR7; 16 were located within the highly conserved regions, indicating
cross-reactivity of T cells among HAdV-subspecies. Ten epitopes induced CD4+-proliferation in N50% of
individuals, conﬁrmed by intracellular IFN-γ detection. Three SCT recipients who recovered from an infection
with HAdV displayed reactivity towards only a single hexon epitope, whereas healthy individuals were
responsive to two to eight epitopes (median 3). The ex vivo detection of Hexon-speciﬁc CD4+ T-cells,
without any long-term culture in vitro, enables the detection and generation of HAdV-speciﬁc CD4+ T cells
for adoptive T-cell transfer against HAdV-infection post SCT.
© 2009 Elsevier Inc. All rights reserved.Introduction
Adenoviral (HAdV) infections are relevant causes of morbidity and
mortality in immunocompromised patients, especially in recipients of
an allogeneic hematopoietic stem cell transplantation (SCT) (Hand-
gretinger et al., 2001; Lang et al., 2003; Mohty et al., 2003). In children
post SCT, adenovirus has become the most common viral pathogen,
responsible for systemic infections or localized infections of the
gastrointestinal tract, upper and lower airway and urinary tract (Lion
et al., 2003; Walls et al., 2003; Flomenberg et al., 1994). Increased
frequencies of severe HAdV infections have also been detected in solid
organ transplant recipients (Shirali et al., 2001) and in human
immune-deﬁciency virus (HIV)-positive patients (Kojaoghlanian et
al., 2003). An increased risk of adenovirus infection correlates with
the lack of corresponding endogenous T-cell immunity (Chakrabarti
et al., 2002; Feuchtinger et al., 2005; Heemskerk et al., 2005). Drug
therapy could be efﬁcient to limit, but not cure the infection
(Chakrabarti et al., 2002; Heemskerk et al., 2005; Feuchtinger et al.,en.de (T. Feuchtinger).
ll rights reserved.2005; Feuchtinger et al., 2006; Yusuf et al., 2006). This has led to
efforts to improve the detection and isolation of HAdV-speciﬁc T cells
by the characterization of their T-cell epitopes. The detection of
HAdV-speciﬁc T cells may improve the risk assessment of patients
with HAdV infection and the isolation may facilitate adoptive transfer
of HAdV-speciﬁc T cells from the donor into the recipient to restore
protective immunity. The T-cell response against HAdV has been
described predominantly speciﬁc for capsid proteins (Molinier-
Frenkel et al., 2000), adenoviral Hexon protein being the immunodo-
minant region (Molinier-Frenkel et al., 2002). Among adenovirus
species and subtypes, the amino acid sequence of the Hexon protein
can be subdivided into hypervariable and conserved regions (Rux
et al., 2003). MHC-I restricted peptides have been identiﬁed,
demonstrating that adenovirus-speciﬁc T cells can be either broadly
cross-reactive or reactive to a restricted spectrum of viral strains
(Leen et al., 2004; Tang et al., 2006). MHC-II restricted peptide
epitopes within the Hexon protein have been described, with one
HLA-DP (Tang et al., 2004; Leen et al., 2008), six with undeﬁned HLA
restriction pattern (Olive et al., 2002; Veltrop-Duits et al., 2006), ﬁve
HLA-DR17 and DP4 restricted Hexon epitopes (Heemskerk et al.,
2006), and three HLA-DRB1 restricted epitopes (Onion et al., 2007). In
a recent study, ﬁve CD4 epitopes were identiﬁed in the Hexon protein
Table 1
Amino acid sequences of predicted MHC-II restricted peptides from the Hexon protein
(swissprot database entry P04133).
No. Amino acid sequence Mass Position Score Predicted HLA
restriction
3545 GTAYNALAPKGAPNP 1440.7 117–131 36 DR1
3534 QWSYMHISGQDASEY 1440.7 8–22 32 DR1
3542 TETLTKVKPKTGQEN 1672.9 422–436 24 DR1
3540 TGNMGVLAGQASQLN 1459.7 341–355 32 DR1
3526 VDCYINLGARWSLDY 1786.8 513–527 36 DR1
3547 EWNFRKDVNMVLQSS 1851.9 581–595 33 DR3
3549 GASIKFDSICLYATF 1634.8 604–618 31 DR3
3590 THDVTTDRSQRLTLR 1797.9 52–66 30 DR3
3592 PGSYTYEWNFRKDVN 1874.9 575–589 28 DR4
3621 TLRFIPVDREDTAYS 1781.9 64–78 28 DR4
3594 SQWYETEINHAAGRV 1759.8 208–222 28 DR4
3595 ENGWEKDATEFSDKN 1768.8 435–449 28 DR4
3597 GNNFAMEINLNANLW 1719.8 454–468 28 DR4
3551 ATFFPMAHNTASTLE 1636.8 616–630 28 DR4
3619 GWAFTRLKTKETPSL 1733.9 676–690 28 DR4
40002 LMYYNSTGNMGVLAG 1589.7 335–349 32 DR7
3625 FKKVAITFDSSVSWP 1709.9 717–731 30 DR7
3623 DPYYTYSGSIPYLDG 1709.7 695–709 30 DR7
3596 PQKFFAIKNLLLLPG 1698 562–576 30 DR4, DR7
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26 HAdV-speciﬁc T-cell lines (Leen et al., 2008). All these epitopes
were either identiﬁed or characterized using HAdV-speciﬁc T-cell
lines, which have been repetitively stimulated in vitro. Diagnostic
tools for the detection of HAdV speciﬁc T cells and an adoptive T-cell
transfer require (i) epitopes with known HLA-binding pattern, (ii)
dominant epitopes that are recognized by the majority of healthy
donors and by patients recovering from HAdV infection and (iii)
epitopes with an antigenicity that enables an ex vivo detection of a
speciﬁc T-cell response without long-term culture steps in vitro.
In this paperwe therefore selected 19 candidate CD4 epitopes with
predicted restriction to HLA-DR1, -DR3, -DR4 and -DR7 using the
SYFPEITHI database. With these peptides 44 healthy donors and 5
patients post SCTwere tested for the presence of Hexon-speciﬁc CD4+
responses. Ten epitopes showed a proliferation response in N50% of
individuals with major differences in the response of healthy donors
and patients post SCT.
Results
Alignment of Hexon protein sequences of different adenovirus
strains/subtypes
An alignment of the sequences of 51 different adenovirus subtypes
shows the known conserved and hypervariable regions of the
adenoviral Hexon protein (Fig. 1). The localization of the deﬁned
CD4 T-cell epitopes is in the highly conserved regions for 16 peptides
and in variable regions for 3 peptides. Localization of an epitope in a
conserved region means, that the corresponding THELPER-cell response
is most probably cross-reactive against different adenovirus subtypes.
Analysis of THELPER-cell responses ex vivo
We investigated the responseof CD4+Tcells inhealthydonors against
the candidate Hexon epitopes. All out of 19 predicted epitopes listed in
Table 1 showed a speciﬁc T-cell response in at least one donor, but the
number of responding donors was variable. An epitope was considered
immunodominant, if a reactivity was found in more than 50% of tested
individuals. Among 19 tested epitopes, 10 were found immunodominant
(Fig. 2): one epitope predicted for promiscuous DR4/DR7 presentation
(3596), three epitopes predicted for HLA-DR1 presentation (3534, 3545,
3540), one epitope forHLA-DR3 (3549), four epitopes forHLA-DR4 (3592,
3596, 3619, 3621) and three epitopes predicted forHLA-DR7 (3596, 3623,
40002). The antigen speciﬁc proliferation responsewasmainlywithin the
CD4+ T-cell population (Fig. 2).
The antigen speciﬁc proliferation response of CD4+ T cells was
conﬁrmed by intracellular IFN-γ detection after ex vivo stimulation
with peptides. This method allows a quantiﬁcation of speciﬁc T cells in
peripheral blood and is important for antigen detection and selection
of Ag-speciﬁc T cells. The frequency of peptide-speciﬁc T cells inFig. 1. Alignment of the sequences of Hexon proteins from the 51 different adenovirus sub
regions with low similarity. In the upper panel the localization of the identiﬁed Hexon pepti
reactivity of the corresponding T-cell responses to several adenovirus subtypes. Three epitoperipheral blood is rather low. Sixteen out of 19 peptides showed a
response above the detection threshold of 0.01% (% of viable T cells)
(Fig. 3). All ex vivo responses to peptide epitopes represented only a
fraction of the response to complete Hexon protein, which means in
all donors the response to Hexon protein was a multi-epitope
response.
Individual response pattern to different Hexon epitopes
All 44 healthy donors showed an individual response pattern. The
combination as well as the quantity of the CD4+ T-cell response was
different among donors. All healthy donors had THELPER-cell responses
against two or more Hexon epitopes, with a median reactivity against
three (2–8) epitopes (mean 3.5±1.4 SD). Some donors showed a
strong response to epitopes, which are recognized only by a minority
of donors. As an example for this phenomenon serves peptide 3597,
which is recognized by only 20% of donors (Fig. 2), but induced a
strong response comparable to the immunodominant epitope 3592
(Fig. 3). Three peptides (3540, 3592 and 3621) showed a proliferation
response almost as high as the percentage of donors responding to
Hexon protein (Fig. 2).
THELPER-cell response to HLA-DR epitopes in patients after recovery from
HAdV infection post allogeneic SCT
Analysis of speciﬁc CD4+ T-cell response to HLA-DR binding
Hexon peptides was performed in six patients post allogeneic SCT.types: The alignment shows conserved regions with high similarity and hypervariable
des is shown. In the conserved regions are 16 out of 19 epitopes, which suggests cross-
pes (40002, 3540 and 3597) are in variable regions.
Fig. 2. Frequency of CD4+ T-cell responses to Hexon epitopes among 44 healthy donors. T-cell proliferation was assessed ex vivo by CFSE and is shown in response to recombinant
protein and to HLA-DR restricted peptides. Every panel represents a different group of donors (n=11 each panel) with an HLA type corresponding to the predicted HLA-DR
restriction of the epitopes. If more than 50% of healthy donors responded to peptides, the epitope was termed immunodominant, since only 70–90% of healthy donors have
detectable cellular response ex vivo to the adenoviral Hexon protein.
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response was detectable in patients only after recovery from an
HAdV infection (patient nos. 1–3). In patients without a preceding
infection, no HAdV-speciﬁc T-cell response was detectable (patient
nos. 4–6). In all samples with a Hexon-speciﬁc T-cell response, a
reactivity of CD4+ T cells to HLA-DR-restricted peptides was found.
A reactivity to a maximum of one epitope per patient could be
detected.
CD4+ T cells showed strong proliferation response to single
HLA-DR epitopes. In contrast to healthy donors, the reactivity in
patients post SCT was focused to single epitopes (Fig. 4), whereas
healthy donors demonstrated always multi-epitope responses. The
restriction after SCT of the THELPER cell response to single epitopeswas conﬁrmed in these three patients by detection of intracellular
IFNγ (Fig. 4B).
HLA-DR restriction pattern of Hexon-epitopes
The HLA-DR restriction of Hexon epitopes was assigned by their
binding probability according to SYFPEITHI. This algorithm-based
prediction of HLA allele-speciﬁc presentation was re-examined in
vitrowith Elispot assays. All peptides were grouped according to their
HLA-binding prediction and used as an antigen cocktail in Elispot
assay. In donors expressing HLA-DR1, -DR3, or -DR4 the strongest
response is seen to the cocktail matching the HLA restriction (Fig. 5).
In donors with a mismatched HLA type, the response was negative or
Fig. 3. Quantiﬁcation of Hexon-speciﬁc T-cell response in intracellular cytokine staining: The frequency of peptide-speciﬁc T cells was measured by intracellular IFN-γ staining after
stimulation with antigen ex vivo. The quantitative analysis of the IFN-γ response to HLA-DR binding peptides is shown in comparison to complete protein (mean±SD). Every panel
represents a different group of donors with an HLA type corresponding to the HLA-DR restriction of the epitopes. A detectable cytokine response is seen even in non-
immunodominant donors. The frequency of peptide-speciﬁc T cells in peripheral blood is rather low. Sixteen out of 19 peptides showed a response above the detection threshold of
0.01% (of viable T cells).
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prediction.
One peptide was found to be a promiscuous HLA-DR epitope,
recognized by HLA-DR1, -DR3, -DR4 and -DR7 donors. Promiscuous
recognition of peptide 3596 was conﬁrmed by two different methods,
intracellular IFN-γ detection and CFSE proliferation assays. PBMC
responses were tested from four donors with mutual exclusive HLA-
DR typing regarding HLA-DR1, -DR3, -DR4 and -DR7. Intracellular IFN-
γ detection by ﬂow cytometry in response to 3596 stimulation and
proliferation response in CFSE assays have shown equivalent
responses to stimulation with 3596. The response of CD4+ T cells tothis epitope in different HLA background conﬁrmed the promiscuous
nature of this epitope (data not shown).
Discussion
Characterization of the speciﬁc T-cell immune response to
adenovirus is a precondition for immunotherapy approaches
that target the prevention of infection related complications in
the immunocompromised host. The presence of a detectable CD4
T-cell immunity has been shown essential to overcome potential
life threatening HAdV infection/reactivations post allogeneic SCT
Table 2
Patient characteristics of SCT recipients after recovery from HAdV infection (nos. 1–3) and patients without HAdV infection (nos. 4–6) post allogeneic SCT.
Patient
no.
Clinical data Immune reconstitution at time of HAdV
































MMF 194–210 stool diarrhea 260 MMF 3750 19,6 16,7 3,3
2 16 ALL haplo Flu, TT, TLI,
OKT3, ATG
MMF 78–174 stool diarrhea 244 – 2520 69,3 53 27,4













MMF – – – 84 – 1800 16,6 14,6 1,4
5 14 ALL MUD TBI, VP16,
ATG






MMF – – – 100 – 1440 84,9 35,2 51,7
Abbreviations: ALL (acute lymphoblastic leucemia), SCID (severe combined immune deﬁciency), MUD (matched unrelated donor), haplo (the SCT donor is the father or mother), Flu
(Fludarabin), TT (Thiotepa), Mel (Melphalan), OKT3 (Muronomab), MMF (mycophenolate mofetil), CSA (Cyclosporin A), ATG (anti thymocyte globulin), TLI (total lymphoid
irradiation), GvHD (graft versus host disease.
Patient nos. 1–3 had a detectable HAdV speciﬁc T-cells response in contrast to patient nos. 4–6.
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CD8 T-cell epitopes have been recently identiﬁed (Olive et al., 2002;
Tang et al., 2004; Leen et al., 2004). Application of these data to clinical
diagnostic and therapeutic procedures is hampered by different
hurdles. The frequency of the T-cell response in healthy donors (as a
source for immunotherapy) is extremely low or unknown with often
uncertain immunodominance and HLA-binding pattern. We have
stimulated T cells from healthy donors ex vivo with 19 HLA-DR
binding epitopes using proliferation and IFN-γ secretion of CD4 T cells
as a readout to identify immunodominant epitopes, HLA-restriction
and differences between healthy donors and the immunocompro-
mised host.
The T-cell response to hexon protein is driven towards a
predominance of THELPER cells. Flomenberg et al. described already
in 1995, that the T-cell response to adenovirus is predominantly CD4.
Here we show that the same is true for the hexon protein. However,
the T-cell response in in vitro assays may also depend on the nature of
the antigen. Using protein antigens, the in vitro response may be
driven towards THELPER cells.
The percentage of donors responding to a Hexon epitope
showed a wide range between 10% and 80% of donors. In addition,
every donor showed an individual response pattern to Hexon
epitopes. These ﬁndings underline the importance of analyzing
immunodominance, since a response of a single donor or T-cell
line to a single epitope could hardly predict a relevance of this
epitope in other healthy donors or even an immunocompromised
host. The quantity of response detected by IFN-γ secretion ex vivo
was independent of the response prevalence among healthy
donors. Above a threshold of 0.01% an isolation of virus speciﬁc
T cells has been possible for adoptive T-cell therapy (Feuchtinger
et al., 2004, 2006; Feuchtinger et al., 2008; Leen et al., 2008).
According to this threshold 16 peptides would be eligible for an
adoptive T-cell transfer, since the ex vivo response is strong
enough in healthy donors.
The analysis of the acute immune response in immunocompetent
humans is difﬁcult, because primary infections are mainly during
infancy and early childhood. These infections are normally mild and
do not require blood analysis. Therefore the analysis of the acute
immune response is restricted to the immunologically unusual
situation post SCT in which T-cell activation, proliferation and the
T-cell spectrum is markedly altered (Eyrich et al., 2001). We show in
three examples post SCT, that the polyclonal response in healthydonors in narrowed to single epitopes during the response to HAdV
post SCT. These responses to single epitopes are involved in the acute
response to a HAdV infection. Additionally they are likely to be
involved in the clearance of HAdV infection in these three patients,
since patients without a HAdV infection post SCT had no detectable
T-cell response. T-cell depletion during SCT is one possible
explanation for the absent T-cell response in patients without a
HAdV-infection. T-cell depletion leaves SCT recipients with a naive
immune system and protective immunity has to be reestablished
through infections or vaccinations.
The clinical applicability of T-cell epitopes is additionally
inﬂuenced by the HLA-binding pattern of identiﬁed epitopes and
the potential cross-reactivity among different HAdV subtypes. HLA-
binding could be clariﬁed in 15 out of 19 peptides (except DR7).
Restriction of epitopes to a certain HLA-type reduces the
availability of possible immunotherapeutic applications with this
antigen, since even frequent HLA-types represent minorities in the
transplant population.
In conclusion, immunodominance, quantiﬁcation of CD4 T-cell
response and HLA-restriction has been characterized in 19 HLA-DR
binding peptides of the adenoviral Hexon protein. Single epitopes
appear to be involved in the recovery from HAdV infection post SCT.
These data may provide information to translate data on T-cell
epitopes into diagnostic and therapeutic clinical application. The
current study indicates that in adoptive T-cell transfer strategies, the
use of entire hexon (or a mixture of capsid proteins) provides a
broader spectrum and hence an inductive response is more likely,
compared to single epitope approaches.
Material and methods
Healthy donors and patients post SCT
Blood samples from healthy donors were received from the local
Transfusion Medicine. Patient samples were from children with HAdV
infection post allogeneic SCT within the ﬁrst 6 months after SCT.
Patients were treated in the Pediatric Stem Cell Transplant Program of
the University Children's Hospital Tübingen. The patient character-
istics and transplant data are summarized in Table 2. None of the
patients received immunosuppressive treatment at the time of T-cell
analysis. All donors and patients gave informed consent. The analysis
of blood samples was reviewed by the ethical institutional review
Fig. 4. Patients after recovery from HAdV infection post allogeneic stem cell transplantation show a narrowed T-cell response against single epitopes in comparison to a multi-epitope response in healthy donors. Proliferation responses are
shown in three children with HAdV infection during the ﬁrst year post allogeneic SCT (panel A, left column of graphs) and representative proliferation responses in three healthy donors with the same HLA type (panel A, right column of
graphs). The intensity of the response was similar to responses seen in healthy donors, but patients responded solely to single epitopes. In contrast, healthy donors always showed a response to multiple epitopes. The proliferation results
shown in Panel A are conﬁrmed with the detection of intracellular IFN-γ by ﬂow cytometry (panel B). These responses to single epitopes are likely to be involved in the acute response to a HAdV infection. Additionally they are likely to be











Fig. 5. HLA-DR restriction of Hexon peptides in Elispot assays performed with PBMC of
healthy donors. Ex vivo IFN-γ response against mixed peptides pools was tested in
healthy donors. PBMCs were stimulated ex vivo with HLA-DR restricted peptide mixes
(HLA-DR1 mix: 3534, 3542, 3545, 3526, 3540; HLA-DR3 mix: 3547, 3549, 3590; HLA-
DR4: 3551, 3592, 3594, 3595, 3597, 3619, 3621; HLA-DR7: 3623, 3625, 40002). IFN-γ
expression was then measured by IFN-gamma ELISPOT (SFC=Spot Forming Cells/
5×105 PBMCs). Donors expressed each one of the four HLA-DR types (HLA-DR1, -DR3,
-DR4, -DR7) and were negative for the three other ones. The response to the HLA-DR1,
-DR3 and -DR4 restricted peptides showed a pattern according to the predicted HLA
restriction while the response to HLA-DR7 restricted peptides did not follow the
prediction (mean±SD).
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Declaration of Helsinki.
Prediction of CD4+ T-cell epitopes
The sequence of Hexon protein from human adenovirus serotype 5
(sequence obtained from the swissprot database at http://www.
expasy.ch, Accession No. P04133) was screened for candidate
epitopes ﬁtting to HLA-DR peptide motifs using the SYFPEITHIdatabase (www.syfpeithi.de). From all possible 15mer sequences,
the top scoring peptides were selected as follows: From the DR1, DR3,
and DR7 predictions, all peptides with scores higher than 30 were
chosen for synthesis (11 peptides in total). Since 28 is the maximal
score in HLA-DR4 predictions, all nine peptides scoring 28 in the DR4
prediction were also selected. Since peptide 3596 ranked high in two
different DR predictions, the total number of synthesized peptides
was 19 (see Table 1).
Proliferation assays
Proliferation was detected with CFSE (Carboxyﬂuorescein succi-
nimidyl ester, Molecular Probes, Eugene, OR, USA) according to a
recently published protocol (Feuchtinger et al., 2008; De Rosa et al.,
2003). PBMCs were enriched by Ficoll® separation and washed with
PBS. CFSEwas then added to the cells to a ﬁnal concentration of 1.6 μM
in PBS and cells were incubated for 9 min at 37 °C. CFSE was then
neutralized by Fetal Bovine Serum and washed off with RPMI 1640®.
PBMCs were resuspended in RPMI 1640 with 10% AB serum to a ﬁnal
concentration of 2.5×106 cells/ml. After stimulation by addition of
the respective peptides at a concentration of 10 μg/ml, the stained
cells were incubated in a 96 well plate, cell proliferation was ﬁnally
assessed by ﬂow cytometry. A positive response was deﬁned as N10%
above background proliferation in the unstimulated negative controls.
Positive controls were carried out with Staphylococcal enterotoxin B
(SEB, Sigma Chemical, St. Louis, USA).
Flow cytometry
Ag-speciﬁc T cells were detected as described recently (Feuchtinger
et al., 2005). In brief, peripheral blood mononuclear cells (PBMC) were
stimulated ex vivo with either 10 μg/ml Hexon peptides or 6 μg/ml
Hexon protein from type 2 adenovirus (Virion-Serion GmbH,
Würzburg, Germany), or viral lysate. The lysate was derived from a
HAdV strain isolated from peripheral blood of a pediatric patient after
SCT, who suffered from systemic HAdV infection type C. The viral
particles were inactivated with 65 °C for 30 min. Positive responses
were conﬁrmed with a concentration of 1 μg/ml peptides for
stimulation. T cells with antigen-speciﬁc secretion of IFN-γ were
detected on the following day. Flow cytometric assessment of IFN-γ
secretion of viable T cells was carried out by intracellular cytokine
staining. Surface staining was performed using saturating conditions
of the following antibodies: anti-CD4 or anti-CD8 (clones SK3 or SK1),
anti-IFN-γ (clone 25723.11), anti-CD3 (clone SK7), all from Becton
Dickinson (BD) or BD Pharmingen (Heidelberg, Germany). At least
100,000 lymphoid cells were analyzed on a FACS-Calibur with
Cellquest software (both from BD). Negative and positive controls
were carried out with unstimulated samples and staphylococcal
enterotoxin B (SEB, Sigma Chemical). Experiments were evaluated
only when unstimulated controls were negative and response to SEB
was positive. Although control antigens did not usually stimulate any
IFN-γ production, the percentage of speciﬁc T cells was calculated by
subtraction of the frequency obtained by the respective negative
control. Negative controls were carried out with isotype staining,
unstimulated controls and irrelevant peptides.
Elispot assays
The Elispot assay was performed using Multiscreen-HA® plates
(Millipore SA., Molsheim, France) coated with monoclonal anti-human
IFN-γ antibody (Mabtech AB, Clone 1-D1K, Hamburg, Germany). After
incubation of 5×106 cells/ml (100 μl/well) for 20 h at 37 °C with
peptides/antigen, positive controls, biotinylated anti-human IFN-γ
(both Mabtech AB, Clone 7B 6-1) was added. Thereafter, staining was
performed with an Avidin-Peroxidase-Komplex, and Vectastain Elite
ABC-Kit (Vector Laboratories, Burlingame, CA, USA) according to the
284 C. Serangeli et al. / Virology 397 (2010) 277–284manufacturer's instructions with 3-Amino-9-Ethylcarbazole-substrate
(Sigma-Aldrich, Steinheim, Germany) andDimethylformamide (Merck,
Darmstadt, Germany). Results were analyzed in triplicate on an
automated Elispot reader (Aelvis, Hannover, Germany).
Alignment of Hexon protein sequence
The alignment was done, using Vector-NTI Advance 10 software.
The complete Hexon amino acid sequences of all 51 different
adenovirus subtypes were retrieved from the NCBI database
(http://www.ncbi.nlm.nih.gov/sites/entrez). The NCBI database
entry were (HAdV1–HAdV51): AP_000512, P03277, AAO24079,
AAD03654, P04133, AAZ99997, AAC35275, AAZ99998, BAE66671,
AAZ99999, AAP49209, P19900, ABA00000, AAZ99996, ABA00001,
P36854, NP_597869, AAZ99994, ABA00002, ABA00003, AAG21823,
ABA00004, ABA00005, ABA00006, ABA00007, ABA00008, ABA00009,
ABA00010, ABA00011, ABA00012, AAZ99995, ABA00013, ABA00014,
BAB20014, BAB20015, ABA00015, ABA00016, ABA00017, ABA00018,
CAA36077, P11820, ABA00019, ABA00020, ABA00021, ABA00022,
ABA00023, ABA00024, ABO61301, ABA00025, ABA00027 and
ABA00026.
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